RadNet, Inc. research snapshot
RDNT AI stock analysis as of the August 3, 2026 data cutoff reads RadNet, Inc. as a fast-growing U.S. outpatient diagnostic imaging operator with an AI software arm, trading at a premium valuation with a cash burn question. The stock closed at $63.78 on July 31, 2026 with a market capitalization near $5.02 billion and an enterprise value near $6.49 billion, re-verified during this full refresh against StockAnalysis.com, SEC EDGAR XBRL, the Q1 2026 Form 10-Q, and the Q1 2026 earnings release and call. The Q1 2026 report, released May 10, 2026, delivered record first quarter revenue of $575.6 million, up 22.1%, and record adjusted EBITDA of $63.3 million, up 36.3%, with advanced imaging procedure volume up 19.7% and same-center advanced imaging up 8.2%, and management raised full-year 2026 imaging center guidance for revenue, adjusted EBITDA, and free cash flow. Digital Health revenue rose 51.5% to $29.1 million, and annual recurring revenue reached $96.9 million, up 95% year over year, on a path to over $114 million by year-end. On July 30, 2026, DeepHealth announced FDA 510(k) clearance for its AI-powered breast ultrasound, an upside catalyst Jefferies highlighted. Offsetting the momentum are a trailing GAAP net loss near $14.2 million on a TTM basis, FY2025 net income of negative $18.65 million, an EV/EBITDA near 22.5 times, net debt near $1.48 billion on the March 31, 2026 balance sheet, about 12.8% of shares sold short, a barometer high of $85.84 hit in November 2025 versus a current price near $63.78, and public commentary questioning the company as a cash burning business. This is informational research and not investment advice.
Current price
$63.78
Market cap
$5.02 billion
AI score
52 / 100
Rating
Strong growth at a premium valuation with a cash burn question
Trend status
Ranging below the 200-day moving average near $66.55 and above the 50-day near $59.27
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | RadNet is the largest U.S. provider of freestanding, fixed-site outpatient diagnostic imaging services by number of locations, with 435 imaging centers plus a DeepHealth Digital Health software business, delivering TTM revenue near $2.14 billion. | High |
| Moat | The moat combines national scale in imaging centers, regional market density, a growing base of health system joint ventures such as the Saint Alphonsus partnership, and a DeepHealth AI portfolio with 26 FDA clearances, though routine imaging services face reimbursement and competition pressure. | Medium |
| Management | Dr. Howard Berger has led RadNet for decades with CFO Mark Stolper, and the team is executing a buy and build strategy across imaging centers and AI, raising 2026 guidance after a record Q1, with insider ownership near 10.3%. | Medium |
| Financial trend | Revenue rose from $1.32 billion in 2021 to $2.04 billion in 2025, Q1 2026 revenue grew 22.1%, adjusted EBITDA grew 36.3% to $63.3 million, and 2026 imaging center guidance was raised to $2,355 to $2,405 million in revenue, but GAAP net income was negative in FY2025 and TTM, and Digital Health adjusted EBITDA fell to $1.3 million in Q1 2026 on investment spending. | Medium-high |
| Valuation | At about 2.34 times sales, 49 times trailing free cash flow, and 22.5 times EV/EBITDA, with forward PE cited between 87 and 124 depending on the adjusted EPS basis, the stock trades at a premium that assumes continued strong growth. | Medium |
| Technical trend | RDNT closed at $63.78 on July 31, 2026, above its 50-day moving average near $59.27 but below its 200-day near $66.55, with 14-day RSI near 56, implying a neutral to cautious ranging posture between support and the 200-day line. | Medium |
| Risk level | Key risks are persistent GAAP losses, net debt near $1.48 billion with Debt/EBITDA near 6.7 on an S&P basis, Medicare reimbursement proposals for 2027, acquisition integration, AI monetization risk, about 12.8% short interest, and a premium multiple. | Medium-high |
| AI confidence | High for descriptive facts and cross-checked math that matched across StockAnalysis.com, SEC EDGAR XBRL, the Q1 2026 earnings release, the Q1 2026 Form 10-Q, and the earnings call transcript. Lower for forward return estimates because reimbursement, leverage, and AI ramp assumptions are uncertain. | High data confidence |
| Investment certainty | Low to medium certainty. The page gives a research framework and scenario ranges, not a buy or sell instruction. | Low to medium |
RDNT AI stock forecast
The RDNT AI stock forecast uses scenario math around the July 31, 2026 close of $63.78, the analyst average target of $89.75, and the FY2026 revenue estimate near $2.49 billion. The three-scenario framework produced a bearish area near $50, a base area near $84, and a bullish area near $100 over a one to three year horizon, using revenue and adjusted EBITDA growth assumptions and valuation multiples between 18 and 24 times EV/EBITDA. These are scenarios, not price commitments.
$92 to $108
More likely if advanced imaging volume keeps growing at a double digit rate, DeepHealth ARR exceeds the $114 million year-end target, AI deployment visibly cuts RadNet operating expenses, Medicare reimbursement for 2027 comes in favorable, GAAP profitability turns positive, and the market holds a premium multiple.
$74 to $92
More likely if RadNet compounds revenue at a high teen rate, keeps raising guidance as Q1 2026 did, maintains adjusted EBITDA margin expansion, and the stock moves toward the analyst average target of $89.75 as integration and AI deployment proceed.
$46 to $58
More likely if Medicare reimbursement proposals pressure imaging center economics, acquisition spending and interest costs outpace free cash flow, GAAP losses persist, Digital Health monetization takes longer than guided, or the premium EV/EBITDA multiple compresses toward 16 to 18 times.
RDNT AI technical analysis
RDNT AI technical analysis is neutral to cautiously positioned as of the August 3, 2026 data cutoff. The stock closed at $63.78 on July 31, 2026, above its 50-day moving average near $59.27 but below its 200-day moving average near $66.55, with 14-day RSI near 56. Barchart lists first resistance near $64.95 with a 200-day line near $66.55 overhead, and first support near $62.05 with the 50-day line near $59.27 below, while the November 25, 2025 52-week high of $85.84 remains far overhead.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $63.78 | StockAnalysis.com real-time quote at the July 31, 2026 close, up 1.74% on the day; market cap math uses 78.63 million shares outstanding. |
| Near resistance | $64.95 to $67.85 | Barchart lists first resistance near $64.95, second near $66.12, and third near $67.85, with the 200-day moving average near $66.55 adding overhead. |
| Near support | $62.05 to $59.15 | Barchart lists first support near $62.05, second near $60.32, and third near $59.15, which aligns with the 50-day moving average near $59.27. |
| 50-day moving average | $59.27 | StockAnalysis.com statistics reported the 50-day moving average near $59.27 on July 31, 2026, below the current price and a first pullback reference. |
| 200-day moving average | $66.55 | StockAnalysis.com statistics reported the 200-day moving average near $66.55, above the current price and the key trend level to reclaim for a bullish technical shift. |
| 52-week range | $50.76 to $85.84 | The 52-week low of $50.76 was set around August 7, 2025 and the high of $85.84 on November 25, 2025, so the stock sits below the upper third of its range. |
| Momentum | RSI near 56 | StockAnalysis.com reported 14-day RSI near 56.39 on July 31, 2026, neutral rather than overbought, while Barchart assigned a weak buy technical opinion near 24% with a weakening short term outlook. |
| Volume | About 597,000 shares | StockAnalysis.com reported volume near 596,121 on July 31, 2026 versus a 20-day average near 681,742, normal activity for a small cap health stock. |
| Volatility | High near earnings | Barchart reported implied volatility near 61.8% with an IV percentile near 80%, so options imply a wider expected move into the August 9 to 10, 2026 earnings date. |
| Invalidation | Close below $59.15 | A decisive close below the $59.15 third support and the 50-day moving average near $59.27 would weaken the short term range; reclaiming the 200-day near $66.55 would signal a bullish shift. |
RDNT AI trading strategy
The RDNT AI trading strategy is a rules-based research framework, not personal advice. It should be paired with fresh chart data, the Q2 2026 report expected August 9 to 10, 2026, Medicare reimbursement news, cash flow trends, position sizing, and a defined invalidation level.
Watch for RDNT to reclaim and hold the 200-day moving average near $66.55 and the $67.85 third resistance with rising volume, which would confirm a shift from the current ranging posture above the 50-day near $59.27.
A daily close below the $59.15 third support and the 50-day near $59.27 should trigger a stop and review, especially with about 12.8% of shares short and high implied volatility into earnings.
If RDNT pulls back toward the $59.15 to $62.05 support zone without new reimbursement, leverage, or guidance damage, compare the price reaction with Q2 results, margin guidance, and Digital Health ARR before acting.
Do not average down without a maximum loss rule because a disappointing Medicare proposal, a weaker Q2 report, or an acquisition misstep can turn a support zone into a value trap.
Track same-center advanced imaging volume, imaging center adjusted EBITDA margin, 2026 guidance execution, Digital Health ARR toward the $114 million year-end target, free cash flow versus acquisition and interest spending, net debt to adjusted EBITDA near 2 times, and 2027 Medicare Physician Fee Schedule proposals.
Reduce confidence if GAAP losses widen, leverage rises well above 2 times net debt to adjusted EBITDA, or revenue growth depends mainly on acquisitions rather than same-center volume and Digital Health.
Investment research summary
RadNet sells outpatient diagnostic imaging services, mostly MRI, CT, PET/CT, mammography, ultrasound, and X-ray, through 435 freestanding centers, and sells radiology AI and informatics software under the DeepHealth brand, so patients, referring physicians, payers, and health system partners pay for access to imaging capacity, clinical quality, and AI-driven workflow efficiency.
The moat is scale plus density plus emerging software. RadNet is the largest U.S. freestanding imaging operator, with regional clusters, health system joint ventures, long-standing referring relationships, and a DeepHealth portfolio with 26 FDA clearances and 22 CE marks that is increasingly embedded in its own and third-party workflows.
The thesis fails if Medicare reimbursement proposals for 2027 cut imaging economics, acquisition and de novo spending outpaces free cash flow and raises leverage above manageable levels, GAAP losses persist without a clear inflection, DeepHealth monetization slips against a $114 million ARR target, radiologist or technologist shortages throttle volume, or the premium EV/EBITDA multiple compresses.
Dr. Howard Berger and CFO Mark Stolper have run RadNet for decades through a buy and build model, delivering record Q1 2026 revenue and adjusted EBITDA, raising 2026 guidance, closing imaging center acquisitions in Florida and Indiana plus the Gleamer AI acquisition, and launching the Saint Alphonsus joint venture, with insider ownership near 10.3%.
Outpatient diagnostic imaging demand is growing with an aging population, and advanced imaging is structurally outpacing routine imaging, while radiology faces physician shortages and backlogs that create a durable opening for AI workflow tools such as DeepHealth Reporting Pro and TechLive.
At about $63.78, a $5.02 billion market cap, 2.34 times sales, 49 times trailing free cash flow, and 22.5 times EV/EBITDA, the stock is priced for continued high growth, so the margin of safety is thinner than it was below $55, and it depends on whether revenue and EBITDA growth plus AI cost savings can justify the premium.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RDNT price | $63.78 at the July 31, 2026 close, up 1.74% on the day | StockAnalysis.com real-time quote | August 3, 2026 |
| Market capitalization | $5.02 billion market cap and $6.49 billion enterprise value, computed with 78.63 million shares outstanding | StockAnalysis.com statistics | August 3, 2026 |
| Q1 2026 results | Total company revenue of $575.6 million, up 22.1%, adjusted EBITDA of $63.3 million, up 36.3%, and adjusted diluted loss per share of $0.28, versus a $0.34 loss a year ago | RadNet Q1 2026 earnings release | May 10, 2026 |
| Q1 2026 GAAP results | GAAP net loss attributable to RadNet of $33.5 million, or $0.43 per diluted share, matching SEC EDGAR XBRL, after $8.7 million of earnings attributed to noncontrolling interests | RadNet Q1 2026 Form 10-Q and SEC EDGAR XBRL | August 3, 2026 |
| Q1 2026 volume and mix | Aggregate advanced imaging volume up 19.7% and same-center advanced imaging up 8.2%, with advanced imaging at 29.3% of procedure volume versus 26.9% a year ago, and PET/CT up 35.2% on a systemwide basis | RadNet Q1 2026 earnings release and earnings call | May 11, 2026 |
| Digital Health revenue and ARR | Digital Health revenue of $29.1 million in Q1 2026, up 51.5%, with annual recurring revenue of $96.9 million as of March 31, 2026, up from $49.8 million a year ago, on a path to over $114 million by year-end | RadNet Q1 2026 earnings release and earnings call | May 11, 2026 |
| 2026 imaging center guidance | Revenue raised to $2,355 to $2,405 million, adjusted EBITDA raised to $340 to $353 million, and free cash flow raised to $112 to $122 million; Digital Health guidance reaffirmed at $135 to $145 million revenue and $10 to $12 million adjusted EBITDA before non-capitalized R&D | RadNet Q1 2026 earnings release | May 10, 2026 |
| FY2025 revenue and net income | FY2025 revenue of $2,040 million, up 11.5%, with GAAP net income of negative $18.65 million, both matching SEC EDGAR XBRL (2040210000 revenue and -18652000 net income) | StockAnalysis.com financials and SEC EDGAR XBRL 10-K | August 3, 2026 |
| TTM financials | TTM revenue of $2,144 million with TTM GAAP net income of negative $14.19 million, TTM operating cash flow of $336.31 million, and TTM free cash flow of $101.96 million | StockAnalysis.com financials and statistics | August 3, 2026 |
| Cash and debt | Cash of $455.3 million, total debt of $1,934 million, and net debt of $1,479 million as of March 31, 2026, matching SEC EDGAR XBRL cash of 455339000; net debt to adjusted EBITDA was slightly below 2.0 per management | RadNet Q1 2026 Form 10-Q and SEC EDGAR XBRL | August 3, 2026 |
| Q1 2026 operating cash flow | Operating cash flow of $78.97 million in Q1 2026 versus $41.48 million in Q1 2025, matching SEC EDGAR XBRL, with days sales outstanding at a record low of 29.5 days | RadNet Q1 2026 Form 10-Q, earnings call, and SEC EDGAR XBRL | August 3, 2026 |
| Valuation | 2.34 times sales, 49.19 times trailing free cash flow, 4.64 times book value, 22.50 times EV/EBITDA, 3.03 times EV/sales, and forward PE of 87.37 on the statistics page versus 123.67 on the forecast page for FY2026 due to different adjusted EPS bases | StockAnalysis.com statistics and forecast | August 3, 2026 |
| Analyst consensus | Strong Buy with an average price target of $89.75 across 8 analysts, low $65 and high $100, median $93.50, with targets last updated May 20, 2026 | StockAnalysis.com forecast | July 22, 2026 |
| Recent analyst target updates | Barclays lowered to $65 from $70 on May 20, 2026, Truist reiterated $90 on May 19, Jefferies raised to $95 from $91 on May 14, B. Riley lowered to $83 from $87 on May 1, and KeyBanc maintained $92 on April 29 | StockAnalysis.com forecast | July 22, 2026 |
| FY2026 and FY2027 consensus | FY2026 revenue estimate of $2.49 billion, up 21.95%, and FY2027 revenue of $2.74 billion, up 10.29%; FY2026 adjusted EPS of $0.52 and FY2027 of $0.94, with three year revenue growth forecast near 14.65% and three year EPS growth near 46.15% | StockAnalysis.com forecast and statistics | July 22, 2026 |
| Short interest | 10.04 million shares short, 12.76% of shares outstanding, 15.15% of float, and 9.35 days to cover | StockAnalysis.com statistics | August 3, 2026 |
| FDA clearance catalyst | DeepHealth received FDA 510(k) clearance on July 30, 2026 for its AI-powered breast ultrasound, with more than 98% accuracy in localizing breast lesions and radiologist interpretation time reduced by 37%, targeted for implementation across RadNet by year-end with an estimated over 700,000 annual breast ultrasound studies eligible for reimbursement | DeepHealth press release via GlobeNewswire | July 30, 2026 |
| FDA and CE mark portfolio | DeepHealth holds 26 FDA clearances and 22 CE marks, with an additional 12 FDA clearances and 15 CE marks expected before the end of 2026, and regulatory approval velocity up over 70% year over year | RadNet Q1 2026 earnings call | May 11, 2026 |
| Acquisitions and joint ventures | Closed imaging center acquisitions of Radiology Regional in Southwest Florida and Northwest Radiology in Indiana in January 2026, acquired Gleamer SAS in France on March 2, 2026, and launched a Saint Alphonsus Health System joint venture on April 30, 2026 with 155 of 444 centers held within health system partnerships | RadNet Q1 2026 earnings release and earnings call | May 11, 2026 |
| Debt financing | RadNet secured a $250 million incremental term loan on June 10, 2026 to fund strategic growth and reduced interest rates on its credit facility by 0.25% | RadNet press release via GlobeNewswire | June 10, 2026 |
| Technical snapshot | 50-day moving average near $59.27, 200-day moving average near $66.55, 14-day RSI near 56.39, 20-day average volume near 681,742, implied volatility near 61.8% with IV percentile near 80%, and Barchart resistance near $64.95, $66.12, and $67.85 with support near $62.05, $60.32, and $59.15 | StockAnalysis.com statistics and Barchart | August 3, 2026 |
| Next earnings date | Q2 2026 earnings expected on August 9, 2026 after market close per StockAnalysis.com, or August 10, 2026 before market open per Barchart | StockAnalysis.com statistics and Barchart | August 3, 2026 |
This RDNT AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, Medicare reimbursement proposals, market moves, acquisition news, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
